RXRX Q2 2024 Earnings — Recursion Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

RXRXRecursion Pharmaceuticals, Inc.

$2B

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$14M+30.8% YoY

Gross Profit

$5M36.1% margin

Operating Income

-$101M-698.0% margin

Net Income

-$98M-677.2% margin

EPS (Diluted)

$-0.40

QoQ Revenue Growth

+6.8%

Cash Flow

Operating Cash Flow

-$82M

Free Cash Flow

-$86M

Stock-Based Comp.

$17M

Balance Sheet

Total Assets

$776M

Total Liabilities

$191M

Stockholders' Equity

$584M

Cash & Equivalents

$474M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$14M	$11M	+30.8%
Gross Profit	$5M	$2M	+218.5%
Operating Income	-$101M	-$82M	-23.0%
Net Income	-$98M	-$77M	-27.1%

Revenue Segments

License and Service

$14M100%

Grant

$13,0000%